


Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Zhongzhi Pharmaceutical Holdings Limited

中智藥業控股有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 3737)

POLL RESULTS OF 2025 ANNUAL GENERAL MEETING

The Board is pleased to announce that all resolutions proposed at the AGM held on 13 May 2025 were duly passed by the Shareholders by way of poll at the AGM.

Reference is made to the notice of annual general meeting (the “**AGM**”) and the circular of the Company (the “**Circular**”) both dated 17 April 2025. Capitalized terms used herein shall have the same meanings as defined in the Circular unless the context requires otherwise.

The Board is pleased to announce that all the proposed resolutions as set out in the notice of AGM dated 17 April 2025 were duly passed by the Shareholders by way of poll at the AGM held on 13 May 2025.

As at the date of the AGM, the total number of Shares in the issued share capital of the Company was 863,600,000 Shares. There were no Shares entitling the Shareholders to attend and abstain from voting in favour of any of the resolutions proposed at the AGM. None of the Shareholders were required to abstain from voting at the AGM. Accordingly, there were a total of 863,600,000 Shares, representing the entire issued share capital of the Company, entitling the Shareholders to attend and vote for or against the resolutions proposed at the AGM. No Shareholders has stated their intention in the Circular to vote against or to abstain from voting on the resolutions at the AGM.

The Company’s branch share registrar and transfer office in Hong Kong, Union Registrars Limited, was appointed as the scrutineer at the AGM for the purpose of vote-taking.

The poll results in respect of all the resolutions at the AGM are set out as follows:

ORDINARY RESOLUTIONS		Number of Votes (approx. %)	
		FOR	AGAINST
1.	To receive and approve the audited consolidated financial statements and the reports of the directors and the auditor of the Company for the year ended 31 December 2024	595,685,000 (100.0000%)	0 (0.0000%)
2.	(a) the declaration and payment of a final dividend of HK5 cents per ordinary share out of the Share Premium account of the Company (the “ Final Dividend ”) to shareholders of the Company whose names appeared on the register of members of the Company on the record date fixed by the board of directors (the “ Board ”) for determining the entitlements to the Final Dividend be and is hereby approved; and (b) any director of the Company be and is hereby authorised to take such action, do such things and execute such further documents as the director may at his absolute discretion consider necessary or desirable for the purpose of or in connection with the implementation of the payment of the Final Dividend	595,685,000 (100.0000%)	0 (0.0000%)
3.	(a) to re-elect Mr. Lai Ying Feng as an executive director of the Company	595,616,000 (99.9884%)	69,000 (0.0116%)
	(b) to re-elect Ms. Jiang Li Xia as a non-executive director of the Company	595,685,000 (100.0000%)	0 (0.0000%)
	(c) to re-elect Mr. Ng Kwun Wan as an independent non-executive director of the Company	595,616,000 (99.9884%)	69,000 (0.0116%)
	(d) to re-elect Mr. Zhu Sangheng as an independent non-executive director of the Company	595,685,000 (100.0000%)	0 (0.0000%)
4.	To authorise the Board to fix the remuneration of all the directors of the Company for the year ending 31 December 2025	595,685,000 (100.0000%)	0 (0.0000%)
5.	To re-appoint Ernst & Young as the auditor of the Company and to authorise the Board to fix their remuneration for the year ending 31 December 2025	595,684,000 (99.9998%)	1,000 (0.0002%)

ORDINARY RESOLUTIONS		Number of Votes (approx. %)	
		FOR	AGAINST
6.	To grant a general mandate to the directors of the Company to repurchase shares of the Company not exceeding 10% of the total number of issued shares of the Company	595,685,000 (100.0000%)	0 (0.0000%)
7.	To grant a general mandate to the directors of the Company to allot, issue and deal with additional shares in the Company not exceeding 20% of the total number of issued shares of the Company	590,361,000 (99.1062%)	5,324,000 (0.8938%)
8.	To extend the general mandate granted to the directors of the Company to allot, issue and deal with shares by the number of shares repurchased	590,361,000 (99.1062%)	5,324,000 (0.8938%)

On the basis of the votes set out above, the above resolutions numbered 1-8 were duly passed as ordinary resolutions.

All Directors attended the AGM accordingly.

By order of the Board
Zhongzhi Pharmaceutical Holdings Limited
Mr. Lai Zhi Tian
Chairman and Executive Director

Hong Kong, 13 May 2025

As at the date of this announcement, the Board comprises eight directors. The executive directors are Mr. Lai Zhi Tian, Mr. Lai Ying Feng, Mr. Lai Ying Sheng and Mr. Cao Xiao Jun. The non-executive director is Ms. Jiang Li Xia. The independent non-executive directors are Mr. Ng Kwun Wan, Mr. Zhu Shangheng and Mr. Zhou Dai Han.